The Food and Drug Administration (FDA) has approved Arbli™, an oral suspension formulation of losartan potassium.  Arbli, an angiotensin II receptor blocker, is indicated for the treatment of ...

Taking losartan with other drugs that work in the same way may increase the chance of low blood pressure, high potassium levels in the blood, and kidney damage. NSAIDs may also reduce the blood ...

Scienture shares originally traded higher on Tuesday but have since reversed and began trading lower after the company ...

The company has committed to refraining from additional draws on the ELOC for either 30 trading days or until its share price reaches $10, demonstrating confidence in its near-term business prospects.

Scienture (SCNX) announces the U.S. Food and Drug Administration, FDA, has approved SCN-102, one of the products being developed by Scienture, ...

The angiotensin II type 1 receptor antagonist (angio-tensin receptor blocker [ARB]) losartan has been shown in the LIFE (Losartan Intervention for Endpoint Reduction in Hypertension) study to ...

[18] The usual starting dosage of losartan potassium is 50 mg once daily. The dosage can be increased to a maximum of 100 mg daily. Doses exceeding 100 mg have not been found to produce any ...

Arbli is supplied as an peppermint-flavored oral suspension containing 10mg/mL of losartan potassium in 165mL bottles. The Food and Drug Administration (FDA) has approved Arbli ™, an oral ...